Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34461749 | 0.81 | ADORA2A (0.41) | ADORA2AADORA3ADORA2BTP53ALDH1A1 | |
| SCHEMBL34461750 | 0.81 | ADORA2A (0.38) | ADORA2AADORA3ADORA2BMCL1ALDH1A1 | |
| SCHEMBL34461729 | 0.71 | ALDH1A1 (0.35) | ADORA2AADORA3ADORA2BMCL1MAPK1 | |
| SCHEMBL4259212 | 0.71 | MPO (0.62) | — | |
| SCHEMBL34461751 | 0.69 | MPO (0.42) | MCL1ALDH1A1 | |
| SCHEMBL3521372 | 0.68 | NPC1 (0.53) | ALDH1A1MAOAMAOBPOLB | |
| SCHEMBL34461705 | 0.63 | ADORA2A (0.46) | ADORA2ATP53ALDH1A1MAOBMAPT | |
| SCHEMBL23053810 | 0.60 | ALDH1A1 (0.46) | MCL1ALDH1A1POLB | |
| SCHEMBL14761683 | 0.60 | CYP1A2 (0.40) | MCL1ALDH1A1MAOAMAOB | |
| SCHEMBL3524552 | 0.60 | MAOA (0.45) | TP53ALDH1A1MAOAMAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2026-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | WRN, POLR1A, REV1 | ADORA2A 586/4885ADORA3 613/4885ADORA2B 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.